Clinical trial for Cancer
Official title Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
ClinicalTrials.gov ID: NCT07454499
What this study is testing
- What it's testing
- The study aims to learn how to help patients understand and manage side effects from hormone therapy. It will also look at ways to help women stay on their treatment for the recommended time.
- Who it's for
- The study is looking for women who are taking hormone therapy for breast cancer.
- What's involved
- Participants will use a mobile health tool to monitor their symptoms and receive health promotion support.
- Time commitment
- The source text does not specify the duration or visit schedule for this study.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Participants must identify as a woman
- Participants must be age 18 or older
- Participants must have a diagnosis of Stage 0, I, II, or III HR+ breast cancer
- Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or...
- Participants must have completed surgery for treatment of breast cancer at least 14 days prior to randomization.
You likely can't join if
- Metastatic (Stage IV) breast cancer
- Male gender
- Prior treatment with endocrine therapy for breast cancer
- Communication difficulties such as: Uncorrected or uncompensated hearing and/or vision impairment, uncorrected or uncompensated speech defects...
See the full eligibility criteria
- Participants must identify as a woman
- Participants must be age 18 or older
- Participants must have a diagnosis of Stage 0, I, II, or III HR+ breast cancer
- Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole) within 16 weeks of study registration.
- Participants must have completed surgery for treatment of breast cancer at least 14 days prior to randomization.
- Participants who received chemotherapy must have finished it at least 14 days prior to randomization.
- Speak and read in English
- Own an internet-enabled cell phone
- Capable of using the electronic pill bottle
- Concomitant radiotherapy is allowed. Concomitant maintenance targeted or biologic therapy (e.g., anti-HER2 therapy, osteoclast inhibitor therapy, CDK 4/6 inhibitor, ovarian function suppression medications) is allowed.
- Metastatic (Stage IV) breast cancer
- Male gender
- Prior treatment with endocrine therapy for breast cancer
- Communication difficulties such as: Uncorrected or uncompensated hearing and/or vision impairment, uncorrected or uncompensated speech defects, uncontrolled psychiatric/mental condition or severe physical, neurological...
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.